NasdaqGS:ROIVBiotechs
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Long Term Bullish Narratives
Roivant Sciences (ROIV) just posted its FY 2026 third quarter scorecard, with total revenue of US$2.0 million and a basic EPS loss of US$0.38, set against a trailing 12 month basic EPS loss of US$1.17 and revenue of US$13.31 million. Over recent periods the company has seen quarterly revenue move between US$4.48 million and US$9.02 million in FY 2025, while quarterly basic EPS losses have ranged from US$0.17 to US$0.33. That combination of modest top line and sizable losses keeps the focus...